Compare OMDA & RGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OMDA | RGNX |
|---|---|---|
| Founded | 2011 | 2008 |
| Country | United States | United States |
| Employees | 868 | N/A |
| Industry | Medical/Nursing Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 711.1M | 418.1M |
| IPO Year | N/A | 2015 |
| Metric | OMDA | RGNX |
|---|---|---|
| Price | $13.12 | $9.36 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 11 | 8 |
| Target Price | $21.73 | ★ $28.75 |
| AVG Volume (30 Days) | ★ 846.7K | 572.1K |
| Earning Date | 05-17-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 18.08 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $10,393,000.00 |
| Revenue This Year | $24.94 | $50.15 |
| Revenue Next Year | $20.18 | $23.42 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 126.48 |
| 52 Week Low | $10.28 | $5.85 |
| 52 Week High | $26.92 | $16.19 |
| Indicator | OMDA | RGNX |
|---|---|---|
| Relative Strength Index (RSI) | 53.72 | 57.67 |
| Support Level | $10.28 | $7.76 |
| Resistance Level | $16.93 | $10.08 |
| Average True Range (ATR) | 0.77 | 0.50 |
| MACD | 0.02 | 0.17 |
| Stochastic Oscillator | 87.23 | 89.45 |
Omada Health Inc empowers individuals to make lasting health changes through personalized, virtual care between doctor's visits. The integrated platform of the company supports members with cardiometabolic conditions like prediabetes, diabetes, hypertension, musculoskeletal issues, and behavioral health needs. The company's specialized care tracks also assist members using GLP-1 medications. The Company delivers measurable health outcomes and value for employers, health plans, health systems, and pharmacy benefit managers.
Regenxbio Inc is a clinical-stage biotechnology company focused on the development of gene therapy treatments. Its product candidates are designed to deliver genes to cells to address genetic defects or enable the production of therapeutic proteins. The company is developing a pipeline of investigational gene therapy treatments using its NAV Technology Platform based on adeno-associated virus (AAV) vectors. Its internal research and development programs are focused on therapies for retinal, neuromuscular, and neurodegenerative diseases.